Detailed Study on the Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus| Chapter 15 | Current Topics in Medicine and Medical Research Vol. 10

 In most economically developed nations, type 2 diabetes mellitus (T2DM) is now the most prevalent type of diabetes mellitus. Incretin-based therapy for patients with type 2 diabetes mellitus (T2DM) is now a prevalent treatment choice. It has been associated with substantially good results in the management of cardiac or nephron-benefit hyperglycemia. In several clinical recommendations, it is recommended for people with cardiovascular disorders for this purpose. Glucagon-like peptide-1 (GLP-1) has many metabolic advantages as an incretin hormone, such as improving energy use, maintaining body weight, sustaining β cell preservation, and preventing neurodegeneration. Recent research, however, show that oral antidiabetic medicines interfere with endogenous or endogenous products.

GLP-1-exogenous. Since these drugs are transported to portions of the distal intestine, there are questions as to whether these oral drugs specifically activate GLP-1-releasing intestinal L cells or whether they do so by indirectly inhibiting the function of dipeptidyl peptidase IV (DPP-IV). The metabolic relationships between oral anti-hyperglycemic drugs from the stomach, microbiota, hormones, β-cell function, central nervous system, and other cell mechanisms are explored in this study. The results of these studies provide the basis for new drugs or formulations to be established that can ensure a better metabolism of glucose.


Author (s) Details

Thiquynhnga Nguyen
Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.

Min Gong
Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.

Song Wen
Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.

Xinlu Yuan
Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.

Chaoxun Wang
Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.



Jianlan Jin
Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.

Ligang Zhou
Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai 201399, China.

View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/323